Skip to content
Menu
Breaking Efficacy Ceilings
Home
About
Science
Pipeline
News
Careers
Triveni Bio
News
The latest company updates, news, and insights
Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples
Press Release
9.23.2025
Fierce Biotech names Triveni Bio a “Fierce 15” Biotech Company of 2025
Press Release
9.22.2025
Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis
Press Release
5.21.2025
Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disorders
Press Release
10.2.2024
BioPharmaDive News: With $115M more, Triveni accelerates immune drug work
In the News
10.2.2024
FierceBiotech News: Triveni ropes in $115M series B less than a year after $92M fundraise
In the News
10.2.2024
Stifel 2024 Virtual Immunology and Inflammation Summit
In the News
9.18.2024
Triveni Bio Appoints Bhaskar Srivastava, M.D., Ph.D., as Chief Medical Officer, Announces Key Program Updates
Press Release
6.12.2024
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
Press Release
12.13.2023
MedCity News: Biotech Startup Triveni Unveils $92M to Address Barrier to Treating Inflammation
In the News
11.5.2023
Top